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Abstract
Purpose Mitogen- and stress-activated kinases (MSKs) are important substrates of the mitogen-activated protein kinase 
(MAPK)-activated protein kinase family. MSK1 and MSK2 are both nuclear serine/threonine protein kinases, with MSK1 
being suggested to potentially play a role in breast cancer cell proliferation, cell cycle progression, cell migration, invasion 
and tumour growth. The aim of the current study was to assess MSK1 protein expression in breast cancer tumour specimens, 
evaluating its prognostic significance.
Methods A large cohort of 1902 early stage invasive breast cancer patients was used to explore the expression of MSK1. 
Protein expression was examined using standard immunohistochemistry on tissue microarrays.
Results Low MSK1 protein expression was associated with younger age (P = 0.004), higher tumour grade (P < 0.001), 
higher Nottingham Prognostic Index scores (P = 0.007), negative ER (P < 0.001) and PR (P < 0.001) status, and with triple-
negative (P < 0.001) and basal-like (P < 0.001) phenotypes. Low MSK1 protein expression was significantly associated with 
shorter time to distant metastasis (P < 0.001), and recurrence (P = 0.013) and early death due to breast cancer (P = 0.01). 
This association between high MSK1 expression and improved breast cancer-specific survival was observed in the whole 
cohort (P = 0.009) and in the HER2-negative and non-basal like tumours (P = 0.006 and P = 0.024, respectively). Multivariate 
analysis including other prognostic variables indicated that MSK1 is not an independent marker of outcome.
Conclusions High MSK1 is associated with improved breast cancer-specific survival in early stage invasive breast cancer 
patients, and has additional prognostic value in HER2-negative and non-basal like disease. Although not an independent 
marker of outcome, we believe such findings and significant associations with well-established negative prognostic factors 
(age, grade, Nottingham Prognostic Index, hormone receptor status, time to distant metastasis, recurrence and triple-negative/
basal-like status) warrant further examination and validation in independent patient cohorts.
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Background
Mitogen- and stress-activated kinases (MSKs), nuclear ser-
ine/threonine protein kinases, are important substrates of the 
mitogen-activated protein kinase (MAPK)-activated protein 
kinase family [reviewed in (Cargnello and Roux 2011)]. Two 
novel protein kinases, MSK1 and MSK2, were originally 
described by Deak et al. in 1998, based on their significant 
similarity to the N-terminal ribosomal S6 kinases (RSKs). 
Human MSK1 and MSK2 are 63–75% identical to each other, 
and present significant homology to RSKs (approx. 40% sim-
ilarity) (Deak et al. 1998). MSK1 and MSK2 are activated 
through MAPK/ERKs signalling in response to mitotic agents 
such as epidermal growth factor (EGF) and phorbol ester 
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(TPA, 12-O-tetradecanoylphorbol-13-acetate); or through the 
MAPK/p38 pathway in response to stress stimuli such as UV 
radiation, oxidative and chemical stress (Deak et al. 1998). 
Both MSK1 and MSK2 are ubiquitously expressed across a 
variety of tissues, including heart, brain, placenta, lung, liver 
kidney and pancreatic tissue, with predominant expression 
observed in brain, placenta and skeletal muscle (Deak et al. 
1998).
Many transcription factors have been identified as sub-
strates of MSKs, and phosphorylation by MSKs can enhance 
their activity. MSK1/2 can phosphorylate cAMP response 
element-binding (CREB) protein and activating transcription 
factor 1 (ATF1) in response to mitogens and stress; the phos-
phorylation of CREB at Ser133 can regulate the transcription 
of several immediate early (IE) genes, including c-fos, JunB 
and Egr1 (Wiggin et al. 2002). MSKs contribute to regu-
lation of histone H3, a component of the nucleosome, and 
HMGN1 (HMG-14), a chromatin-associated protein. It has 
been shown that stress- and mitogen-stimulated phosphoryla-
tion of histone H3 and HMGN1 in fibroblasts is compromised 
in  MSK1−/−MSK2−/− mice (Soloaga et al. 2003). The physi-
ological function(s) of MSKs remains to be completely deter-
mined; however, it has been suggested that MSK1/2 may have 
a role in regulating the immune system and neuronal function 
[reviewed in (Vermeulen et al. 2009)].
Recent studies have suggested that MSK1 may be impor-
tant in the regulation of breast cancer cell progression, play-
ing a role in steroid-hormone induced breast cancer cell pro-
liferation (Reyes et al. 2014). Depletion of MSK1 has been 
shown to inhibit oestrogen (E2) or progesterone-induced 
breast cancer cell (T-47D) proliferation and tumour growth 
in hormone-dependent breast cancer xenografts (Reyes et al. 
2014). Furthermore, MSK1 participates in G1-S phase tran-
sition and regulates cell cycle-associated gene expression in 
response to hormones, evidenced by the recruitment of MSK1 
to specific PR-binding sites in chromatin (Reyes et al. 2014). 
Breast tumour-associated osteoblast (TAOB)-derived CXCL5 
induced cell migration, and invasion of the breast cancer cell 
lines, MCF-7 and MDA-MB-231, is associated with increased 
MSK1 activation (Hsu et al. 2013). In T-47D breast cancer 
cells, alcohol exposure can cause increased expression and 
activation of proto-oncogene tyrosine-protein kinase (ROS1), 
which induces MSK1 activation through the MAPK/ERKs 
pathway (Lee et al. 2013).
The aim of the current study was to assess MSK1 protein 
expression in a large cohort of breast cancer tumour speci-
mens, evaluating its prognostic significance.
Methods
Clinical samples
This immunohistochemical-based study was performed 
using a cohort of early stage breast cancer patients 
(n = 1902) treated at Nottingham University Hospitals, 
with long-term follow-up, between 1986 and 1998. Infor-
mation on clinical history, outcome and tumour character-
istics was collected and assessed in a standardised manner, 
including age at diagnosis, tumour size, histologic stage 
and grade, Nottingham prognostic index (NPI), lympho-
vascular invasion (LVI), oestrogen receptor (ER), proges-
terone receptor (PR) and human epidermal growth factor 
receptor 2 (HER2) status. ER, PR and HER2 status were 
available for this cohort and have been described previ-
ously (Abdel-Fatah et al. 2010). HER2 positivity expres-
sion was determined by immunohistochemistry (IHC) with 
fluorescence in situ hybridisation (FISH), and FISH was 
performed for the cases with IHC scored as 2+. Basal-
like phenotype was defined as the expression of cytokera-
tin (CK)-5/6 and/or CK-14 expression in 10% or more of 
invasive tumour cells, irrespective of ER, PR or HER2 
status (Rakha et al. 2006). The median age of the patients 
was 55 years (ranging from 18 to 72), and 63.2% (1203 of 
1902) of patients had stage I disease. Breast cancer-spe-
cific survival was defined as the time interval (in months) 
from the date of primary surgery to death resultant from 
breast cancer. The median follow-up time was 177 months 
(ranging from 1 to 308 months). Patients were managed 
under a uniform protocol, where all underwent wide 
local excision (n = 819, 43.1%) or mastectomy (n = 1067, 
56.1%), and approximately half of the patients received 
radiotherapy (n = 1025, 53.9%). Systemic adjuvant treat-
ment was given based on ER, menopausal status and NPI 
values. Patients with ER-positive disease were chosen for 
hormone therapy (n = 674, 35.4%). Patients with ER nega-
tive or premenopausal status were chosen for CMF chemo-
therapy (cyclophosphamide, methotrexate and 5-fluoroura-
cil, n = 320, 16.8%), if they had an NPI value of 3.4 or 
above, whereas patients who had an NPI value less than 
3.4 did not receive adjuvant chemotherapy. This study is 
reported in accordance with REMARK criteria (McShane 
et al. 2005). Nottingham Research Ethics Committee 2 
approved the project under “Development of a molecular 
genetic classification of breast cancer R&D “(No. 03HI01 
REC Ref.C202313)”. The clinicopathologic variables of 
the patient cohort are shown in Table 1.
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TMA construction and immunohistochemistry
MSK1 protein expression was investigated using freshly 
cut 4 µm sections from tissue microarrays and assessed by 
immunohistochemistry. A single 0.6 mm tissue core was 
used for each patient with the core being taken from a rep-
resentative tumour area as assessed by a specialist breast 
cancer histopathologist, as described previously (Abd El-
Rehim et al. 2005). A range of antibodies were assessed 
for suitability with primary antibody specificity being 
confirmed by Western blotting, using a range of breast 
cancer cell line lysates, prior to immunohistochemistry 
(data not shown). TMA sections were dewaxed in xylene 
and rehydrated in ethanol, followed by antigen retrieval, in 
0.01 mol/L sodium citrate buffer (pH6.0), using a micro-
wave, 750W for 10 min then 450W for 10 min. Staining 
was achieved using a Novolink Polymer Detection System 
(Leica, Denmark) according to the manufacturers’ instruc-
tions. Briefly, endogenous peroxidase activity was neu-
tralised with Peroxidase Block reagent for 5 min at room 
temperature, followed by Protein Block reagent for 5 min 
at room temperature, to minimise non-specific interactions 
of the subsequent detection reagents. Primary antibody 
(anti-MSK1, 1: 200, Bethyl Laboratories, USA, 9252) 
was diluted in Bond Primary Antibody Diluent (Leica, 
Denmark) and applied to the tissue for 1 h at room tem-
perature. Immunohistochemical reactions were visualised 
with 3, 3′-diaminobenzidine and counterstained with hae-
matoxylin, dehydrated and fixed in xylene followed by 
mounting with DPX. Positive controls constituted early 
stage breast tumour composite sections of varying grades, 
Table 1  Clinicopathologic variables of breast cancer patient cohort
Variables No. (%)
Age (mean ± SD, years) 54.25 (± 9.77)
 ≤ 40 years 165 (8.7%)
 > 40 years 1736 (91.3%)
 ND 1 (0.1%)
Tumour size (mm) 2.06 ± 1.14
 ≤ 20 mm 1185 (62.3%)
 > 20 mm 708 (37.2%)
 ND 9 (0.5%)
Tumour stage
 I 1203 (63.2%)
 II 531 (27.9%)
 III 160 (8.4%)
 ND 8 (0.4%)
Tumour grade 346 (18.2%)
 I
 II 632 (33.2%)
 III 915 (48.1%)
 ND 9 (0.5%)
NPI 4.16 ± 1.18
 ≤ 3.4 619 (32.5%)
 3.41–5.4 948 (49.8%)
 > 5.4 324 (17.0%)
 ND 11 (0.6%)
Lymphovascular invasion
 Positive 492 (25.9%)
 Negative 1070 (56.3%)
 ND 340 (17.9%)
Operation type
 Mastectomy 1067 (56.1%)
 WLE lumpectomy 819 (43.1%)
 ND 16 (0.8%)
ER status
 Positive 1370 (72.0%)
 Negative 476 (25.0%)
 ND 57 (3.0%)
PR status
 Positive 1035 (54.4%)
 Negative 739 (38.9%)
 ND 128 (6.7%)
HER2 status
 Positive 243 (12.8%)
 Negative 1602 (84.2%)
 ND 57 (3.0%)
Basal status
 Positive 368 (19.3%)
 Negative 1390 (73.1%)
 ND 144 (7.6%)
Triple negative status
 Positive 315 (16.6%)
 Negative 1516 (79.7%)
Continuous data are shown as mean ± standard deviation (SD)
NPI Nottingham prognostic value; WLE wide local excision; ER oes-
trogen receptor; PR progesterone receptor; HER2 human epidermal 
growth factor receptor 2; ND not determined
Table 1  (continued)
Variables No. (%)
 ND 71 (3.7%)
Breast cancer-specific survival
 Alive 1064 (55.9%)
 Dead 505 (26.6%)
 ND 333 (17.5%)
Recurrence
 Present 752 (39.5%)
 Not present 1103 (58.0%)
 ND 47 (2.5%)
Distant metastasis
 Present 579 (30.4%)
 Not present 1310 (68.9%)
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used in initial optimisations, and negative control omitted 
primary antibody.
Staining was assessed at 200× magnification following 
high-resolution scanning (Nanozoomer Digital Pathology 
Scanner, Hamamatsu Photonics). As no cytoplasmic staining 
was observed, only nuclear staining intensity was assessed. 
The staining intensity was categorised as: none (0), weak 
(1), medium (2) and strong (3). The immunohistochemistry 
H-scores were calculated by multiplying the percentage of 
positive tumour cell nuclei by the staining intensity, giv-
ing rise to a score ranging between 0 and 300. The immu-
nohistochemistry methodology was described previously 
(Woolston et al. 2011a, b). 30% of cases were scored by a 
second independent assessor, blind to survival endpoints, 
clinicopathological variables, and other assessors H-scores. 
Good concordance was demonstrated between both scorers 
(single measure intraclass correlation coefficient was 0.881). 
X-tile software was used to generate a non-biased cut point 
that was used to dichotomise immunohistochemical scores 
(Camp et al. 2004).
Statistical analysis
Pearson’s chi-squared test of association (χ2) was used 
to examine the relationship between categorised pro-
tein expression and clinicopathologic factors, or Fisher’s 
exact test if a cell count in a 2 × 2 table was less than 5. 
Kaplan–Meier survival curves were plotted and significance 
was determined using the Log-rank test. The Cox propor-
tional hazards regression model was applied in multivariate 
survival analysis. All differences were considered statisti-
cally significant at the level of P < 0.05. Statistical analysis 
was performed using SPSS 22.0 software.
Results
Immunohistochemical staining
MSK1 demonstrated diffuse nuclear staining with some het-
erogeneity in intensity which varied from weak to intense. 
No cytoplasmic staining was observed. Areas of ductal car-
cinoma in situ (DCIS) showed variable staining intensity in 
some cases. Only cases of invasive cancer were scored. Typi-
cal staining patterns are shown in Fig. 1. TMA cores with 
insufficient tumour cells (< 15%) were not considered in 
the analysis. A total number of 1270 cases with informative 
cores were assessed. MSK1 staining had a median H-score 
of 190 ± 83 and ranged from 0 to 300. X-tile software was 
used to generate a cut point best associated with outcome. 
This indicated an H-score of 115, with 364 cases (28.7%) 
having low expression and 906 cases (71.3%) having high 
expression.
Relationships with clinicopathologic variables
High MSK1 expression was significantly associated with 
patients over 40 years (χ2 = 8.283, df = 1, P = 0.004), lower 
tumour grade (χ2 = 34.505, df = 2, P < 0.001), lower NPI 
value (χ2 = 9.804, df = 2, P = 0.007), ER-positive tumours 
(χ2 = 50.186, df = 1, P < 0.001) and PR-positive tumours 
(χ2 = 41.147, df = 1, P < 0.001). Low MSK1 expression was 
significantly associated with the presence of triple-nega-
tive (χ2 = 56.406, df = 1, P < 0.001) and basal-like tumours 
(χ2 = 13.850, df = 1, P < 0.001). The associations between 
protein expression and clinicopathologic variables are shown 
in Table 2.
Fig. 1  Representative photomicrographs of high and low MSK1 expression. Panel A (high expression) and panel B (low expression) at ×10 
magnification with ×20 magnification inset panel and scale bar representing 100 µm
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Relationships with clinical outcome
Univariable survival analysis showed that low MSK1 expres-
sion was, in the whole patient cohort, significantly associ-
ated with worse breast cancer-specific survival (P = 0.009) 
(Fig. 2). Multivariate analyses including potential confound-
ing factors, namely age at diagnosis, size, histologic stage, 
grade, NPI value, lymphovascular invasion, ER, PR and 
HER2 status (all variables with individual Kaplan–Meier 
statistics of P < 0.05) were carried out to determine MSK1’s 
independent prognostic value. MSK1 expression was not 
an independent indicator of breast cancer-specific survival 
[hazard radio (HR) = 0.899, 95% confidence interval (CI) 
0.696–1.161; P = 0.415].
Low MSK1 expression was also significantly associated 
with the development of distant metastasis (χ2 = 13.850, 
df = 1, P < 0.001), recurrence (including local/regional recur-
rence and distant metastasis) (χ2 = 6.220, df = 1, P = 0.013) 
and breast cancer-related death (χ2 = 6.711, df = 1, P = 0.01).
The prognostic significance of MSK1 protein expression 
was further assessed in different molecular phenotypes of 
breast tumours. As shown in Table 1, 243 (12.8%), patients 
had HER2 + phenotype tumours, 315 (16.6%) patients had 
triple-negative phenotype tumours, and 368 (19.3%) patients 
had basal-like phenotype (as defined in the “methods” sec-
tion) tumours. MSK1 expression was significant in both 
HER2 and basal-like groups (association with outcome 
breast cancer-specific survival) (P < 0.001 and P = 0.022, 
respectively, Fig. 2b, d). This was investigated further in 
the individual subgroups; low MSK1 expression was associ-
ated with adverse breast cancer-specific survival in HER2-
negative patients and patients with non-basal like disease 
(P = 0.006 and P = 0.024, respectively, Fig. 3b, f). No sig-
nificant association was found in other individual subgroups 
(Fig. 3a, c–e). However, when including the previous con-
founding factors in multivariate analysis, MSK1 lost its 
independent prognostic value for breast cancer-specific sur-
vival in both the HER2-negative (hazard ratio = 0.860, 95% 
confidence interval 0.649–1.141; P = 0.295) and non-basal 
like subgroup (hazard ratio = 0.938, 95% confidence interval 
0.695–1.266; P = 0.674).
Discussion
This is the first study to describe the expression of total 
MSK1 protein in breast cancer patient tumour samples 
and to evaluate its prognostic significance. Low MSK1 
Table 2  Associations between MSK1 protein expression and clinico-
pathologic variables
Correlations between MSK1 protein expression and clinicopathologic 
variables was assessed using Pearson’s Ch-square test of association 
(χ2) or Fisher’s exact test if in a 2 × 2 tables and cell count was less 
than 5. Significant P values are indicated by bold font
Variables MSK1 (n = 1270)
Low expression High expression P-value
Age (years)
 ≤ 40 years 49 (3.9%) 74 (5.8%) 0.004
 > 40 years 315 (24.8%) 831 (65.5%)
Tumour size (mm)
 ≤ 20 mm 207 (16.4%) 545 (43.0%) 0.275
 > 20 mm 156 (12.3%) 358 (28.3%)
Tumour stage
 I 227 (17.9%) 540 (42.7%) 0.544
 II 105 (8.3%) 275 (21.7%)
 III 30 (2.4%) 89 (7.0%)
Tumour grade
 I 38 (3.0%) 169 (13.3%) < 0.001
 II 96 (7.6%) 326 (25.8%)
 III 229 (18.1%) 408 (32.2%)
Nottingham prognostic index
 ≤ 3.4 85 (6.7%) 290 (22.9%) 0.007
 3.41–5.4 198 (15.7%) 451 (35.7%)
 > 5.4 79 (6.3%) 161 (12.7%)
Lymphovascular invasion
 Positive 107 (10.1%) 248 (23.4%) 0.263
 Negative 190 (17.9%) 517 (48.7%)
Operation type
 Mastectomy 213 (16.9%) 520 (41.3%) 0.682
 WLE Lumpectomy 147 (11.7%) 378 (30.0%)
ER status
 Positive 205 (16.7%) 704 (57.2%) < 0.001
 Negative 139 (11.3%) 183 (14.9%)
PR status
 Positive 147 (12.3%) 538 (45.0%) < 0.001
 Negative 196 (16.4%) 314 (26.3%)
HER2 status
 Positive 49 (3.9%) 125 (10.1%) 0.894
 Negative 306 (24.6%) 762 (61.4%)
Basal-like status
 Positive 96 (8.1%) 153 (13.0%) < 0.001
 Negative 247 (20.9%) 685 (58.0%)
Triple-negative status
 Positive 104 (8.5%) 109 (8.9%) < 0.001
 Negative 237 (19.4%) 774 (63.2%)
Breast cancer-specific survival
 Alive 577 (41.7%) 342 (24.7%) 0.01
 Dead 259 (18.7%) 207 (14.9%)
Recurrence
 Present 167 (13.5%) 362 (29.3%) 0.013
 Not present 178 (14.4%) 530 (42.8%)
Distant metastasis
 Present 138 (11.0%) 267 (21.2%) 0.002
 Not present 220 (17.5%) 635 (50.4%)
ER oestrogen receptor, PR progesterone receptor, HER2 human epi-
dermal growth factor receptor 2
Table 2  (continued)
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expression was significantly associated with improved breast 
cancer-specific survival (P = 0.009); however, this was not 
significant in multivariate analysis.
High MSK1 expression was significantly associated with 
older patient age, lower tumour grade, lower NPI values, ER-
positive and PR-positive tumours, and clinicopathological 
variables indicative of an improved prognosis. In agreement 
with this, low MSK1 expression was also found to be associ-
ated with the presence of distant metastasis, recurrence and 
death due to breast cancer, as well as the presence of triple-
negative and basal-like disease. As MSK1 expression was 
associated with triple-negative and basal-like disease, the 
prognostic capability of MSK1 expression in these patient 
sub-groups was assessed. Patients with HER2 negative or 
non-basal like diseases had a significantly worse prognosis 
if the tumour expressed low levels of MSK1.
Phosphorylated MSK1 has been shown to be significantly 
overexpressed in chronic UV-exposed murine skin, human 
squamous cell carcinoma (SCC) and poorly differentiated 
nasopharyngeal carcinoma compared with their normal tis-
sue counterparts (Yao et al. 2014; Li et al. 2015). In the 
current study, total MSK1 expression, rather than phospho-
rylated MSK1, was assessed. Total MSK1 expression may 
not be indicative of MSK1 activity within cells; therefore, 
we cannot infer activity in this study. As mentioned before, 
many factors are substrates of MSKs and can be phospho-
rylated by MSK, such as CREB, ATF1, c-fos and histone 
H3 (Wiggin et al. 2002; Soloaga et al. 2003). Antibodies 
Fig. 2  Kaplan–Meier survival curves for breast cancer-specific sur-
vival based on MSK1 expression. Significance was determined using 
the log-rank test. Panel A: high MSK1 (a) and low MSK1 (b) expres-
sion in total patient cohort. Panel B: HER2-negative disease with 
low MSK1 expression (a); HER2-negative disease with low MSK1 
expression (b); HER2-positive disease with high MSK1 expression 
(c); HER2-positive disease with high MSK1 expression (d). Panel 
C: non-triple-negative disease with low MSK1 expression (a); non-
triple-negative disease with low MSK1 expression (b); triple-negative 
disease with high MSK1 expression (c); triple-negative disease with 
high MSK1 expression (d). Panel D: non-basal-like disease with low 
MSK1 expression (a); non-basal-like disease with low MSK1 expres-
sion (b); basal-like disease with high MSK1 expression (c); basal-like 
disease with high MSK1 expression (d). The numbers below the sur-
vival curves are the number of patients at risk at the specified month
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detecting specific MSK1 substrates might be a reflection 
of MSK1 activity in human breast tumour tissue. Low 
expression of H3K27 (with loss of trimethylation of histone 
H3 at Lysine 27) was also associated with adverse overall 
survival in breast (n = 142), ovarian (n = 255) and pancre-
atic (n = 165) cancer patients (Wei et al. 2008). In addition, 
MSK1 activity in vitro (human embryonic kidney 293 cells) 
is tightly regulated by at least six phosphorylation sites; the 
Fig. 3  Kaplan–Meier survival curves for breast cancer-specific sur-
vival based on MSK1 expression in subgroups. Panel A: subgroup 
analysis of HER2-positive disease with high MSK1 expression (a) 
and low MSK1 expression (b). Panel B: subgroup analysis of HER2-
negative disease with high MSK1 expression (a) and low MSK1 
expression (b). Panel C: subgroup analysis of triple-negative disease 
with high MSK1 expression (a) and low MSK1 expression (b). Panel 
D: subgroup analysis of non-triple-negative disease with high MSK1 
expression (a) and low MSK1 expression (b). Panel E: subgroup 
analysis of basal-like disease with high MSK1 expression (a) and 
low MSK1 expression (b). Panel F: subgroup analysis of non-basal-
like disease with high MSK1 expression (a) and low MSK1 expres-
sion (b). The numbers below the survival curves are the number of 
patients at risk at the specified month
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mutation of some sites leads to decreased MSK1 activity or 
inhibition of other phosphorylation sites in MSK1 in cells 
(McCOY et al. 2005). It would be of interest to determine 
MSK1 expression in human tumour tissue by applying 
MSK1 antibodies with different phosphorylation sites and to 
explore whether MSK1 expression is regulated by a specific 
phosphorylation site.
Although MSK1 and MSK2 share similarity, they are dif-
ferent complexes and exert differing effects. Interestingly, 
differential roles of MSK1 and MSK2 in breast cancer cells 
following UV-radiation have been described. UV radia-
tion has been shown to induce activation of the NF-κB p65 
subunit in MDA-MB-231 cells, which is mainly dependent 
on MSK2 rather than MSK1. The depletion of MSK2 was 
found to reduce cell viability following UV radiation, sug-
gesting that MSK2-mediated NF-κB activation is involved 
in regulating cell survival in MDA-MB-231 cells (Jacks and 
Koch 2010). Recently, MSK1 and MSK2 were also found 
to be involved in the regulation of phorbol ester-induced 
activation of trefoil factor 1 (TFF1), a breast cancer marker, 
in MCF-7 cells (Khan et al. 2013). It would be of interest to 
examine the potential differential roles of MSK1 and MSK2 
in breast cancer cell progression, as well as their prognostic 
significance.
Conclusions
The current study demonstrates that low MSK-1 expression 
is significantly associated with adverse breast cancer-spe-
cific survival. Low expression seems to play a more impor-
tant role in certain patient sub-groups, such as those with 
HER2 + or basal-like phenotype disease. This is the first 
report to describe the potential prognostic significance of 
MSK1 expression in breast cancer patients; although not an 
independent marker of outcome, we believe such findings 
and significant associations with well-established negative 
prognostic factors (low expression associating with younger 
age, higher tumour grade, higher Nottingham Prognostic 
Index, negative hormone receptor status, shorter time to 
distant metastasis, and recurrence, and triple-negative/basal-
like status) warrant further examination and validation in 
independent patient cohorts.
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